Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 14/20 | 0.43 |
| ▸ | CNR1 | P21554 | 12/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21506730 | 0.92 | PTGER4 (0.43) | PTGER4CNR2CNR1FAAH | |
| SCHEMBL21458276 | 0.92 | PTGER4 (0.43) | PTGER4CNR2CNR1FAAH | |
| SCHEMBL21458112 | 0.91 | PTGER4 (0.46) | PTGER4CNR2CNR1 | |
| SCHEMBL27323020 | 0.91 | PTGER4 (0.46) | PTGER4CNR2CNR1 | |
| SCHEMBL24991863 | 0.90 | CNR2 (0.41) | PTGER4CNR2CNR1SIGMAR1FAAH | |
| SCHEMBL30292391 | 0.90 | PTGER4 (0.42) | PTGER4CNR2CNR1FAAH | |
| SCHEMBL20541684 | 0.90 | PTGER4 (0.42) | PTGER4CNR2CNR1FAAH | |
| SCHEMBL20541645 | 0.90 | PTGER4 (0.56) | PTGER4CNR2CNR1SIGMAR1 | |
| SCHEMBL21458214 | 0.89 | PTGER4 (0.47) | PTGER4CNR2CNR1FAAH | |
| SCHEMBL31203583 | 0.89 | PTGER4 (0.47) | PTGER4CNR2CNR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2019204523-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | PTGER4 1/4885CNR2 3/4885CNR1 6/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | PTGER4 1/4885CNR2 3/4885CNR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.